Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corporation (NYSE: EW) generates frequent news as a structural heart medical device company focused on therapies for complex valve disease and structural heart failure. Company announcements highlight developments across transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical heart valve technologies, as well as clinical data, regulatory milestones and corporate updates.
News coverage often features clinical trial readouts and registry data for key Edwards platforms, including the SAPIEN TAVR valves, the SAPIEN M3 mitral valve replacement system, and the EVOQUE tricuspid valve replacement system. Releases describe long‑term outcomes from the PARTNER trial series, pivotal ENCIRCLE TMVR results, and real‑world EVOQUE registry findings, with a focus on safety, durability, regurgitation reduction and quality‑of‑life improvements for patients with limited treatment options.
Investors and clinicians can also follow regulatory and guideline‑related updates, such as U.S. Food and Drug Administration approvals for new transcatheter therapies, European CE Mark decisions, and evolving professional society guidelines for aortic, mitral and tricuspid disease management. Corporate news includes earnings releases, financial guidance, share repurchase announcements, participation in major healthcare conferences and leadership transitions disclosed through press releases and 8‑K filings.
In addition, Edwards Lifesciences reports on collaborations and initiatives in the broader cardiovascular ecosystem, such as its founding sponsorship of the American Heart Association’s Heart Valve Initiative. For readers tracking EW news, this mix of clinical, regulatory, financial and partnership updates provides insight into how the company is advancing structural heart therapies and executing its strategy over time.
Edwards Lifesciences (NYSE: EW) said the U.S. District Court for the District of Columbia granted the U.S. Federal Trade Commission's motion for an injunction blocking Edwards' proposed acquisition of JenaValve Technology, and Edwards will not acquire JenaValve.
The company said it disagrees with the decision, reaffirmed its commitment to treating aortic regurgitation (AR), and will continue advancing the SOJOURN transcatheter AR valve and enrolling patients in the JOURNEY pivotal trial. Edwards revised full-year 2026 adjusted EPS guidance to $2.90–$3.05 from $2.80–$2.95 and will provide further updates at its Fourth Quarter earnings call in February.
Edwards Lifesciences (NYSE: EW) announced FDA approval of the SAPIEN M3 transcatheter mitral valve replacement system on December 23, 2025, the first U.S. transseptal transcatheter therapy for mitral regurgitation.
The device is indicated for symptomatic moderate-to-severe or severe mitral regurgitation in patients deemed unsuitable for surgery or TEER, and for mitral valve dysfunction associated with mitral annular calcification. One-year ENCIRCLE pivotal trial data (299 patients) showed 95.7% MR ≤0/1+ and that the trial met all primary and secondary endpoints; the system received CE Mark in April 2025.
Edwards Lifesciences (NYSE: EW) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT, and Scott Ullem, chief financial officer, will also participate.
A live webcast will be available on the company investor relations site at http://ir.edwards.com/, with an archived version posted later the same day. The announcement notes contact emails for media and investor inquiries.
Edwards Lifesciences (NYSE: EW) reaffirmed guidance and outlined strategy for sustainable growth at its annual investor conference on December 4, 2025. Management reiterated 2025 sales growth at the high end of 9%–10% and EPS of $2.56–$2.62. For 2026 the company guided $6.4–$6.8B sales (constant currency, 8%–10% growth) and adjusted EPS of $2.80–$2.95, including dilution from the planned JenaValve acquisition and ~100bps operating margin expansion at midpoint.
2026 segment targets include TAVR $4.6–$4.9B (6%–8% growth), TMTT $740–$780M (35%–45% growth), and Surgical $1.05–$1.13B. Management highlighted long-term targets: ~10% average annual sales growth and TMTT reaching $2B by 2030.
Edwards Lifesciences (NYSE: EW) announced a founding sponsorship of the American Heart Association’s Heart Valve Initiative on November 9, 2025 to improve care for the more than 28 million people with heart valve disease worldwide. The initiative aims to reduce U.S. deaths linked to valve disease (over 60,000 annually) by improving diagnosis, treatment access, clinician training, data collection, hospital certification, public reporting and patient education.
Planned actions span five years and build on the existing Target: Aortic Stenosis program to accelerate earlier recognition and faster treatment.
Edwards Lifesciences (NYSE: EW) announced that Chief Financial Officer Scott Ullem will transition from his CFO role by midyear 2026. The company is initiating a selection process to appoint a new CFO, and Ullem will remain in an advisory role after a successor is named. Management said the planned timing is intended to enable continuity and a smooth transfer of responsibilities during the transition.
Contact information for media and investors was provided. The release includes standard forward-looking statement disclosures and directs readers to the company website for filings and safety information.
Summary not available.
Edwards Lifesciences (NYSE: EW) presented new mitral and tricuspid clinical data at TCT 2025 showing strong patient outcomes.
Key highlights: the ENCIRCLE single-arm pivotal trial (main cohort n=299) met all one-year primary and secondary endpoints with 95.7% MR ≤ 0/1+ and low death and heart-failure hospitalization rates using the SAPIEN M3 system. The EVOQUE TTVR STS/ACC TVT Registry (n=1,034) reported 98% TR ≤ 0/1+, a 14.9% pacemaker rate, 1.3% major bleeding at 30 days, and median hospital stay of 2 days. SAPIEN M3 is approved in Europe (April 2025) and not yet approved in the US; EVOQUE is approved in both US and Europe.
Edwards Lifesciences (NYSE: EW) presented seven-year PARTNER 3 data at TCT 2025 and published results in The New England Journal of Medicine showing sustained benefits and durable valve performance for SAPIEN 3 TAVR versus surgical aortic valve replacement (SAVR).
At seven years, bioprosthetic valve failure was 6.9% for SAPIEN 3 versus 7.3% for SAVR, and reintervention rates were 6.0% vs 6.7%. All-cause and cardiovascular mortality were similar and health-status gains were sustained. Edwards also highlighted >10-year PARTNER program data, including 10-year follow-up of >3,000 PARTNER 2 patients, and noted the SAPIEN platform has treated >1 million patients worldwide.
Edwards Lifesciences (NYSE: EW) will report operating results for the quarter ended September 30, 2025 after market close on Thursday, October 30, 2025. The company will host an earnings conference call on October 30, 2025 at 5:00 p.m. ET to discuss results.
Dial-in numbers to participate are (877) 704-2848 or (201) 389-0893. The call will be available live and archived on the company Investor Relations website at ir.edwards.com. Media contact: Amy Meshulam, 949-250-4009. Investor contact: Mark Wilterding, 949-250-6826.
FAQ
What is the current stock price of Edwards Lifesciences (EW)?
What is the market cap of Edwards Lifesciences (EW)?
